Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene of Beijiing Files for $100 Million IPO in the US

publication date: Oct 20, 2015
BeiGene, a Beijing biopharma, filed to raise $100 million in a US IPO. The company develops novel, molecularly targeted and immuno-oncology drugs to treat cancer. Founded five years ago, BeiGene currently has four drugs in clinical trials and a number of other molecules in preclinical development. Last week, another prominent China novel drug developer, Hutchison China MediTech, also filed for a $100 million US IPO. The two initial offerings run counter to a three-year trend that has taken almost all US-listed China biopharmas private. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital